It was also shown that a potent STAT5 SH2 domain inhibitor, AC-4–130, was beneficial against FLT3-ITD-mediated activation of STAT5 for supressing proliferation and colony formation in FLT3-ITD+ AML primary cells in vitro and in vivo [55]. This evidence concerns the gene STAT5A and acute myeloid leukemia.